Ardelyx, Inc. (ARDX)

Market Cap	1.51B +20.3%
Revenue (ttm)	407.32M +22.1%
Net Income	-61.60M
EPS	-0.26
Shares Out	245.25M
PE Ratio	n/a
Forward PE	483.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,279,536
Open	6.05
Previous Close	6.10
Day's Range	5.95 - 6.17
52-Week Range	3.21 - 8.40
Beta	0.66
Analysts	Strong Buy
Price Target	15.14 (+146.58%)
Earnings Date	Apr 30, 2026

About ARDX

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2014
• Employees: 489
• Stock Exchange: NASDAQ
• Ticker Symbol: ARDX
• Website: https://www.ardelyx.com

Financial Performance

In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price target is $15.14, which is an increase of 146.58% from the latest price.

Price Target

$15.14

(146.58% upside)

Analyst Consensus: Strong Buy